Cambiotics ApS

Cambiotics is a Copenhagen-based biotechnology company founded in 2024 as a spin-off from the University of Cambridge’s MRC Toxicology Unit. The company specializes in developing precision-formulated probiotic solutions designed to address the accumulation of per- and polyfluoroalkyl substances (PFAS), commonly known as forever chemicals, in the human body. Its core innovation centers on non-GMO probiotic strains that interact with PFAS molecules in the gut, supporting the body's natural processes for their excretion. This research is based on scientific discoveries originating from the Patil Lab at the University of Cambridge, which identified gut bacteria capable of bioaccumulating these persistent pollutants.

The company aims to provide actionable health solutions for populations with elevated exposure risks, such as firefighters and military personnel, as well as the health-optimization community. Cambiotics is preparing to initiate its first human clinical trials in the United States and is gearing up for the commercial launch of its debut dietary supplement, branded as 46&, which is scheduled for 2026. Beyond its product development, the company partners with organizations like Quest Diagnostics to offer PFAS blood testing, providing individuals with tools to monitor their exposure levels and make informed health decisions. The startup is backed by international investors including the Collaborative Fund, EIFO, and the BioInnovation Institute.